We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-21.35%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$2.43B
AUM Growth
-$314M
Cap. Flow
-$88.1M
Cap. Flow %
-3.63%
Top 10 Hldgs %
48.1%
Holding
447
New
130
Increased
120
Reduced
90
Closed
66

Top Buys

Rank Stock Value
1
IWM icon
iShares Russell 2000 ETF
IWM
+$38.8M
2
BIIB icon
Biogen
BIIB
+$26M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$23.3M
4
VTRS icon
Viatris
VTRS
+$21M
5
GBT
Global Blood Therapeutics, Inc.
GBT
+$16.2M

Top Sells

Rank Stock Value
1
TLT icon
iShares 20+ Year Treasury Bond ETF
TLT
+$28.9M
2
MRK icon
Merck
MRK
+$17.9M
3
XOM icon
ExxonMobil
XOM
+$14.8M
4
ZGNX
Zogenix, Inc.
ZGNX
+$13.4M
5
LPCN icon
Lipocine
LPCN
+$7.13M

Sector Composition

Rank Sector Weight
1 Healthcare 13.39%
2 Energy 1.08%
3 Technology 0.46%
4 Materials 0.45%
5 Consumer Discretionary 0.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INFI
176
CALL
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$1.67M 0.07%
1,971
– –
FWP
177
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$1.65M 0.07%
10,000
+4,993
+100% +$1.05M
AGIO icon
178
CALL
Agios Pharmaceuticals
AGIO
$2.09B
$1.65M 0.07%
233
+206
+763% +$20.1K
MNTA
179
CALL
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$1.64M 0.07%
+1,000
New +$20.5K
OMER icon
180
CALL
Omeros
OMER
$834M
$1.63M 0.07%
1,489
+992
+200% +$15.4K
AGTC
181
DELISTED
Applied Genetic Technologies Corporation
AGTC
$1.63M 0.07%
124,000
-48,427
-28% -$803K
AMRN
182
CALL
Amarin Corp
AMRN
$299M
$1.58M 0.07%
409
+275
+205% +$12.5K
ENDP
183
PUT
DELISTED
Endo International plc
ENDP
$1.55M 0.06%
224
– –
NUVA
184
CALL
DELISTED
NuVasive, Inc.
NUVA
$1.54M 0.06%
320
-20
-6% -$1.03K
LUMO
185
PUT
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$1.54M 0.06%
48
-107
-69% -$47K
CRDC
186
DELISTED
CARDICA INC COM NEW (DE)
CRDC
$1.52M 0.06%
528,119
+114,679
+28% +$458K
DYAX
187
DELISTED
DYAX CORPORATION
DYAX
$1.52M 0.06%
+79,613
New +$1.9M
ADXS
188
CALL
DELISTED
Advaxis Inc
ADXS
$1.49M 0.06%
+97
New +$23.5K
OCUL icon
189
Ocular Therapeutix
OCUL
$1.83B
$1.48M 0.06%
105,190
+5,190
+5% +$104K
TROVW
190
CALL
DELISTED
TrovaGene, Inc. Warrant
TROVW
$1.48M 0.06%
+2,600
New +$13.6K
SGYPW
191
CALL
DELISTED
Synergy Pharmaceuticals, Inc. - Warrants
SGYPW
$1.48M 0.06%
+2,785
New +$9.81K
PBYI icon
192
CALL
Puma Biotechnology
PBYI
$399M
$1.47M 0.06%
195
+2
+1% +$189
DVAX
193
PUT
DELISTED
Dynavax Technologies
DVAX
$1.46M 0.06%
594
-502
-46% -$14.2K
MNOV icon
194
MediciNova
MNOV
$64M
$1.42M 0.06%
+500,000
New +$1.71M
INSM icon
195
PUT
Insmed
INSM
$22.7B
$1.42M 0.06%
764
+365
+91% +$9.11K
WINT
196
DELISTED
Windtree Therapeutics Inc
WINT
$1.41M 0.06%
+335,968
New +$2.22M
SRNE
197
DELISTED
Sorrento Therapeutics, Inc.
SRNE
$1.4M 0.06%
+167,064
New +$2.66M
ABEO icon
198
Abeona Therapeutics
ABEO
$343M
$1.38M 0.06%
13,628
+7,238
+113% +$961K
TTOO
199
DELISTED
T2 Biosystems, Inc
TTOO
$1.35M 0.06%
31
+12
+63% +$797K
OCRX
200
DELISTED
Ocera Therapeutics, Inc.
OCRX
$1.35M 0.06%
426,544
+46,970
+12% +$181K
6 7
8
9 10

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q3 2015 Portfolio in Review

As of Q3 2015, Sabby Management held 447 positions worth $2.43B, down 11% from $2.74B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Sabby Management withdrew a net $88.1M in Q3 2015, closing 66 positions and reducing 90 holdings. Its most notable exit was iShares 20+ Year Treasury Bond ETF, an estimated $28.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 13% of assets, up from 8.3% a quarter earlier, followed by Energy and Technology.

Against the trend, Sabby Management opened a new position in iShares Russell 2000 ETF worth $35.7M.

  • Sabby Management's largest Q3 2015 buy was iShares Russell 2000 ETF: 327,168 shares worth $35.7M.
  • Sabby Management added most to Mobileye N.V. in Q3 2015, an estimated $8.9M increase.
  • Sabby Management's biggest Q3 2015 reduction was Lipocine, cutting an estimated $7.13M.
  • Sabby Management fully exited iShares 20+ Year Treasury Bond ETF in Q3 2015, selling an estimated $28.9M.
  • Sabby Management's ten largest holdings make up 48% of its $2.43B portfolio in Q3 2015.
  • Sabby Management opened 130 new positions and closed 66 in Q3 2015.
  • Sabby Management's portfolio value fell 11% quarter-over-quarter to $2.43B.

Based on Sabby Management's 13F filing for Q3 2015, filed 16 Nov 2015.